Mallinckrodt Delays Generics Spinoff

Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.

Later
Mallinckrodt has put off its planned generics spinoff • Source: Shutterstock

Mallinckrodt is “suspending” its plan to spin off its specialty generics business, which includes oxycodone and hydrocodone, into a separate company amid market nervousness about the proposed standalone firm’s exposure to potentially big opioid lawsuit payouts.

The company, which is run out of Hazelwood, Missouri and was the largest manufacturer of oxycodone and hydrocodone pain pills...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business